Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy.

Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy.

Item
http://www.wikidata.org/entity/Q38397819
Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling indexEvaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarraysEvaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study.A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot MethodPrognostic value of Ki67 and p53 in patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer: Validation of the cut-off value of the Ki67 labeling index as a predictive factorSupport of a bi-faceted role of estrogen receptor β (ERβ) in ERα-positive breast cancer cellsPathological examination of breast cancer biomarkers: current status in Japan.Estrogen receptor-β in mitochondria: implications for mitochondrial bioenergetics and tumorigenesis.Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival.Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancer.The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
P2860

Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy.

Item
http://www.wikidata.org/entity/Q38397819
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Ki-67 evaluation at the hottes ...... djuvant tamoxifen monotherapy.
@en
type
label
Ki-67 evaluation at the hottes ...... djuvant tamoxifen monotherapy.
@en
prefLabel
Ki-67 evaluation at the hottes ...... djuvant tamoxifen monotherapy.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P6179
P698
P356
P1433
P1476
Ki-67 evaluation at the hottes ...... adjuvant tamoxifen monotherapy
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P6179
P698